Results 21 to 30 of about 2,225,628 (361)

Association between diverticulosis and colonic neoplastic lesions in individuals with a positive faecal immunochemical test [PDF]

, 2017
Background The association between diverticulosis and colonic neoplastic lesions has been suggested, but data in literature are conflicting. This study aimed to investigate such a relationship in patients participating in a colorectal cancer screening ...
Boggi, R., Hassan, C., Lorenzetti, R., Morini, S., Napoli, M., Ridola, L., Tomao, S., Zullo, A.   +7 more
core   +1 more source

Advanced head and neck cancer: Long-term results of chemo-radiotherapy, complications and induction of second malignancies [PDF]

, 2001
Background: Chemo-radiotherapy is superior to radiotherapy alone in the treatment of advanced, inoperable head and neck cancer. The long-term treatment results, the induction of second malignant tumors, and other long-term toxicities are not well defined.
Aydemir, Ü., Hartenstein, R., Munker, Reinhold, Pohlmann, H., Purmale, L., Reitmeier, M., Schorer, H.   +6 more
core   +1 more source

Exploratory Study Comparing End-of-Life Care Intensity between Chinese American and White Advanced Cancer Patients at an American Tertiary Medical Center

Palliative Medicine Reports, 2021
Background: Understanding ethnic disparities in end-of-life care (EOLC) intensity is central to improving outcomes for diverse populations. Although Chinese Americans represent one of the fastest growing ethnic groups in the United States, little is ...
Emma Ernst, Courtney Schroeder, Avery Caz Glover, Tamara Vesel   +3 more
doaj   +1 more source

Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. [PDF]

, 2019
Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer.
de Vere White, Ralph, Ghosh, Paramita M, He, Wei, Hum, Nicholas R, Loots, Gabriela G, Martin, Kelly A, Pan, Chong-Xian, Sebastian, Aimy, Siddiqui, Salma   +8 more
core   +2 more sources

A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers [PDF]

, 2017
Background: Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment.
Bjarnason, Georg A, Edeline, Julien, Escudier, Bernard, Faivre, Sandrine, Fartoux, Laetitia, Germann, Nathalie, Hirte, Hal, Jones, Robert, Mackay, Helen, Oza, Amit, Plummer, Ruth, Pouget, Jean-Christophe, Thistlethwaite, Fiona, Van Cutsem, Eric, Vergote, Ignace   +14 more
core   +1 more source

Advances in Gynecological Cancers

International Journal of Molecular Sciences, 2022
The burden of gynecological cancer constitutes a major focus of public health efforts, as it continues to represent a significant cause of cancer mortality, exerting not only physical and emotional distress but also serious financial strain upon individuals, caregivers, and communities [...]
Michalis Liontos, Oraianthi Fiste, Flora Zagouri, Meletios-Athanasios Dimopoulos   +3 more
openaire   +3 more sources

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. [PDF]

, 2016
Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options.
Alanis, Lourdes, Cho, Sung-Ki, Lee, Edward Wolfgang, Saab, Sammy   +3 more
core   +1 more source

Immunotherapy of lung cancer: An update [PDF]

, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Aman MJ, Anthony HM, Atanackovic D, Bast RC, Bermers AJA, Carbone FR, Chan B, Cohen MH, Dickler M, Dranoff G, Dudley ME, Faradji A, Gotoh K, Grant SC, Kimura H, Kimura Y, Korkolopoulou P, Kradin RL, Krug LM, Krug LM, Liu M, Ma J, Marshall JL, Melioli G, Millar JW, Nemunaitis J, Nikitina E, O'Brien ME, Palmer M, Raez LE, Ratto GB, Salgia R, Smith A, Sterman D, Swisher S, Villalona-Calero MA, Yano T   +36 more
core   +1 more source

Advances in prostate cancer [PDF]

Current Opinion in Oncology, 1999
The causes of prostate cancer reflect a complex interaction between environmental and genetic factors. Improvement in screening has reduced the incidence of prostate cancer, and risk assessment schemata have enhanced therapy, both for localized disease and for locally recurrent prostate cancer.
Charles J, Ryan, Eric J, Small
openaire   +4 more sources

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]

, 2016
BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier, Hurvitz, Sara A, Krop, Ian E, Miller, Kathy, Molnar, Istvan, Reynolds, Joseph G, Riahi, Kaveh, Tripathy, Debu, Verma, Sunil, Wickham, Thomas J, Yardley, Denise A   +10 more
core   +2 more sources